PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-100.00%
Negative revenue growth while AXSM stands at 4.85%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-83.05%
Negative gross profit growth while AXSM is at 4.24%. Joel Greenblatt would examine cost competitiveness or demand decline.
7.21%
EBIT growth below 50% of AXSM's 29.99%. Michael Burry would suspect deeper competitive or cost structure issues.
7.21%
Operating income growth under 50% of AXSM's 29.99%. Michael Burry would be concerned about deeper cost or sales issues.
7.01%
Net income growth under 50% of AXSM's 30.71%. Michael Burry would suspect the firm is falling well behind a key competitor.
8.82%
EPS growth under 50% of AXSM's 30.77%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
8.82%
Diluted EPS growth under 50% of AXSM's 30.77%. Michael Burry would worry about an eroding competitive position or excessive dilution.
0.91%
Share count expansion well above AXSM's 0.13%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.91%
Diluted share count expanding well above AXSM's 0.13%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
1.55%
Positive OCF growth while AXSM is negative. John Neff would see this as a clear operational advantage vs. the competitor.
1.40%
Positive FCF growth while AXSM is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while AXSM stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
91.07%
Positive long-term OCF/share growth while AXSM is negative. John Neff would see a structural advantage in sustained cash generation.
81.18%
Positive OCF/share growth while AXSM is negative. John Neff might see a comparative advantage in operational cash viability.
13.88%
Positive 3Y OCF/share CAGR while AXSM is negative. John Neff might see a big short-term edge in operational efficiency.
98.43%
Positive 10Y CAGR while AXSM is negative. John Neff might see a substantial advantage in bottom-line trajectory.
78.58%
Positive 5Y CAGR while AXSM is negative. John Neff might view this as a strong mid-term relative advantage.
-7.39%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
109.82%
Below 50% of AXSM's 1272.33%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
14.99%
Below 50% of AXSM's 478.18%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-59.15%
Negative 3Y equity/share growth while AXSM is at 18.13%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
8.48%
Positive asset growth while AXSM is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
19.47%
Positive BV/share change while AXSM is negative. John Neff sees a clear edge over a competitor losing equity.
-6.20%
We’re deleveraging while AXSM stands at 1.64%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-18.94%
Our R&D shrinks while AXSM invests at 18.78%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
28.45%
SG&A growth well above AXSM's 14.01%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.